Trial Profile
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Selumetinib (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SeluDex
- 12 Dec 2023 Results assessing the combination of selumetinib with dexamethasone in adult and pediatric patients with relapsed/refractory T- or BCP-ALL harbouring RAS-pathway activating mutations presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Jul 2023 This study has been completed in Denmark, according to European Clinical Trials Database.
- 09 May 2023 Status changed from active, no longer recruiting to discontinued.